Progress on diagnostic and prognostic markers of pancreatic cancer
作者机构：The State Key Laboratory of Bioactive Substance and Function of Natural MedicinesBeijing100050China Key Laboratory of Drug Target Research and Drug ScreenInstitute of Materia MedicaChinese Academy of Medical Science and Peking Union Medical CollegeBeijing100050China Department of Pancreatic CancerTianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for CancerTianjin’s Clinical Research Center for CancerKey Laboratory of Cancer Prevention and TherapyTianjin300060China
出 版 物：《Oncology Research》 (肿瘤学研究（英文）)
年 卷 期：2023年第31卷第2期
页 面：83-99页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：This work was supported by Beijing Natural Science Foundation(7212157,China) CAMS Innovation Fund for Medical Sciences(2021-I2M-1-029 and 2022-12M-JB-011,China) National Natural Science Foundation of China(81703536,China)
主 题：Pancreatic cancer Biomarkers Liquid biopsy Systematic review
摘 要：Pancreatic cancer is a malignant disease characterized by low survival and high recurrence rate,whose patients are mostly at the stage of locally advanced or metastatic disease when first *** diagnosis is particularly important because prognostic/predictive markers help guide optimal individualized treatment *** far,CA19-9 is the only biomarker for pancreatic cancer approved by the FDA,but its effectiveness is limited by low sensitivity and *** recent advances in genomics,proteomics,metabolomics,and other analytical and sequencing technologies,the rapid acquisition and screening of biomarkers is now *** biopsy also occupies a significant place due to its unique *** this review,we systematically describe and evaluate the available biomarkers that have the greatest potential as vital tools in diagnosing and treating pancreatic cancer.
维普期刊数据库